An interventional study of 4-aminopyridine (4-AP) and Placebo in Cocaine Use Disorder (CUD) and Cognitive Impairments, sponsored by Boris Quednow. Recruiting at 1 site in Switzerland. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Boris Quednow · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Cognitive Dysfunction with a site in Switzerland — 17 open to participants now, 21 under way, 3 of them phase 3. Cognitive Dysfunction · Switzerland.
Among the 61 studies in Cognitive Dysfunction with a site in Switzerland, this one is the 33rd largest by planned enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2026, is one of 38 with no phase, reaches primary completion later than 10 of the 20 other live ones, and was the 59th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →17 of the 61 studies in Cognitive Dysfunction with a site in Switzerland are open now. Recruiting first, the newest first:
University of Zurich · Sites in Switzerland
Ages 18+
University of Bern · Sites in Switzerland
Ages 60–85
Mclean Hospital · Sites in Switzerland, United States
Ages 18–35
Société des Produits Nestlé (SPN) · Sites in Switzerland, France, Germany and 3 more countries
Ages 60+
Region Skane · Sites in Switzerland, Australia, Belgium and 7 more countries
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 20 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 7 · Phase 4 2
First in 2010; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 56 across the 48 interventional studies, 96 across the 13 observational. Of the 33 that completed or were terminated, 4 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 61 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Boris Quednow as lead sponsor.
Boris Quednow has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
5 of the studies in Cognitive Dysfunction with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06191965Phase 3Mclean HospitalMitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction | 2027-01-31 |
| NCT06207942Region SkaneStepcare Extended Follow-up Substudy | 2027-01 |
| NCT05710549Lucie BréchetUnderstanding Brain Mechanisms Involved in Autobiographical Memory | 2027-05-01 |
| NCT07532460Boris QuednowThe Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine Users | 2027-08 |
| NCT05708001Lucie BréchetImprovement of Memory in Mild Cognitive Impairment | 2027-09-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 61 studies in Cognitive Dysfunction with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to address the neurobiological basis of cognitive impairments in chronic cocaine users by investigating the potential impact of an acute potassium channel blockade on working memory performance and other cognitive functions.
Chronic cocaine use is associated with impairments in cognitive functions, particularly in working memory, which are thought to contribute to the persistence of addictive behaviors and high relapse rates. Despite the clinical relevance of these cognitive deficits, the underlying neuropharmacological mechanisms remain insufficiently understood.
Preclinical and clinical evidence suggests that potassium channels may play an important role in the regulation of neuronal excitability and cognitive processes, including working memory. However, their contribution to cognitive impairments in individuals with cocaine use disorder has not yet been systematically investigated in humans.
The present study aims to investigate the role of potassium channel modulation in working memory performance in individuals with chronic cocaine use. The study addresses the following key research questions: (1) Does modulation of potassium channels influence working memory performance in individuals with chronic cocaine use? and (2) How are potential effects related to behavioral responses observed during the experimental sessions?
To address these questions, a randomized, controlled, cross-over study will be conducted in participants with a history of chronic cocaine use. Participants will complete a series of neurocognitive tasks assessing working memory and related cognitive domains under controlled experimental conditions. Blood samples will be collected at multiple time points to quantify substance levels and to support the interpretation of behavioral findings. The results of this study may contribute to a better understanding of the neurobiological mechanisms underlying cognitive impairments in cocaine use and inform future research on cognitive dysfunction in substance use disorders.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive fampridine (A) in one experimental session and placebo (B) in the other, in the order A then B.
Drug: 4-aminopyridine (4-AP) · Drug: Placebo
Participants receive placebo (B) in one experimental session and fampridine (A) in the other, in the order B then A.
Drug: 4-aminopyridine (4-AP) · Drug: Placebo
Two doses of fampridine administered during one of the two experimental test sessions.
Matching placebo administered during one of the two experimental test sessions.
Global Working Memory Performance
Working memory performance will be assessed using a cognitive test battery covering different domains of working memory, including visuo-spatial (Spatial Working Memory \[SWM\], total errors; Paired Associates Learning \[PAL\], first trial memory score) and verbal-numeric components (Letter Number Sequencing Task \[LNST\], total score; Letter N-Back Task, discrimination index d'). Individual test scores will be standardized (z-transformation) and combined into a global working memory score according to Vonmoos et al (2013).
Time frame: Baseline and during both experimental sessions
Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP)
Neurofilament light chain (NfL), a marker of axonal integrity, and glial fibrillary acidic protein (GFAP), a marker of microglia activation, levels will be analysed to assess potential drug challenge-related brain structural remodelling or to predict the effect of potassium challenge blockade.
Time frame: Baseline and during both experimental sessions
Subjective ratings of current mood and craving
Subjective ratings of current mood (affective state, stress) and craving, pre- and post-cue exposure. Current affective state will be assessed using the Positive and Negative Affect Schedule (PANAS; positive affect range: 10-50, negative affect range: 10-50) and visual analog scales (VAS; range 0-100, with higher scores indicating greater levels) of affective state and stress burden. Current cocaine craving will be assessed using the Cocaine Craving Questionnaire-Brief (CCQ-Brief; total score range: 10-70, with higher scores representing worse outcomes) and visual analog scales (VAS; range 0-100, with higher scores indicating greater levels) of craving intensity, distinguishing between wanting, needing and having the urge for cocaine.
Time frame: Baseline and during both experimental sessions
Adverse effects of the study drug
Potential adverse effects of the study drug will be assessed using the List of Complaints and visual analog scales (VAS; range 0-100, with higher scores indicating greater levels) of perceived effects of the substance, dizziness, drowsiness, nausea and impaired concentration.
Time frame: During both experimental sessions
Plasma concentration
Plasma concentration of the study drug
Time frame: During both experimental sessions
Heart rate variability
Heart rate variability is recorded during the test sessions to measure the level of stress and to investigate whether the physiological strain of the test is reduced when taking the study drug.
Time frame: During both experimental sessions
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Aug 2027, 15 months after the start.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 15 months is below that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 4-Aminopyridine